Registro:

Referencias:

• Ross, C.A., Tabrizi, S.J., Huntington's disease: from molecular pathogenesis to clinical treatment (2011) Lancet Neurol, 10 (1), pp. 83-98. , Jan
• Zuccato, C., Valenza, M., Cattaneo, E., Molecular mechanisms and potential therapeutical targets in Huntington's disease (2010) Physiol Rev, 90, pp. 905-981
• Renna, M., Jimenez-Sanchez, M., Sarkar, S., Rubinsztein, D.C., Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases (2010) JBiol Chem, 285, pp. 11061-11067
• Roze, E., Saudou, F., Caboche, J., Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments (2008) Curr Opin Neurol, 21, pp. 497-503
• Johnson, C.D., Davidson, B.L., Huntington's disease: progress toward effective disease-modifying treatments and a cure (2010) Hum Mol Genet, 19 (REVIEW ISSUE 1), pp. R98-R102
• Ross, C.A., Shoulson, I., Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics (2009) Parkinsonism Relat Disord, 15 (S3), pp. S135-S138
• Paradisi, I., Hernández, A., Arias, S., Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation (2008) JHum Genet, 53, pp. 127-135
• Wexler, N.S., Lorimer, J., Porter, J., Gomez, F., Moskowitz, C., Shackell, E., U.S.-Venezuela Collaborative Research Project (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset (2004) Proc Natl Acad Sci, 101, pp. 3498-3503
• Gusella, J.F., MacDonald, M.E., Huntington's disease: the case for genetic modifiers (2009) Genome Med, 1, p. 80
• Aziz, N.A., Jurgens, C.K., Landwehrmeyer, G.B., van Roon-Mom, W.M.C., van Ommen, G.J.B., Stijnen, T., Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease (2009) Neurology, 73, pp. 1280-1285
• Nørremølle, A., Budtz-Jørgensen, E., Fenger, K., Nielsen, J.E., Sørensen, S.A., Hasholt, L., 4p16.3 haplotype modifying age at onset of Huntington disease (2009) Clin Genet, 75, pp. 244-250
• Harper, P.S., The epidemiology of Huntington's disease (1992) Hum Genet, 89, pp. 365-376
• Andrew, S.E., Hayden, M.R., Origins and evolution of Huntington disease chromosomes (1995) Neurodegeneration, 4, pp. 239-244
• Warby, S.C., Visscher, H., Collins, J.A., Doty, C.N., Carter, C., Butland, S.L., HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia (2011) Eur J Hum Genet, 19, pp. 561-566
• Chang, C.M., Yu, Y.L., Fong, K.Y., Wong, M.T., Chan, Y.W., Ng, T.H., Huntington's disease in Hong Kong Chinese: epidemiology and clinical picture (1994) Clin Exp Neurol, 31, pp. 43-51
• Nakashima, K., Watanabe, Y., Kusumi, M., Nanba, E., Maeoka, Y., Nakagawa, M., Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan (1996) Neuroepidemiology, 15, pp. 126-131
• Hayden, M.R., MacGregor, J.M., Beighton, P.H., The prevalence of Huntington's chorea in South Africa (1980) SAfr Med J, 58, pp. 193-196
• Alonso, M.E., Ochoa, A., Boll, M.C., Sosa, A.L., Yescas, P., López, M., Clinical and genetic characteristics of Mexican Huntington's disease patients (2009) Mov Disord, 24, pp. 2012-2015
• Cuba, J.M., Torres, L., Genealogic trees of families with Huntington's chorea in Cañete (Peru) (1989) Rev Neurol, 145, pp. 482-484
• Velez, M., Cosentino, C., Torres, L., Huntington disease in Perú (1998) Mov Disord, 13, p. 221
• Gatto, E., Micheli, F., Fernández, M., Casas Parera, I., Giannaula, R., Análisis de una serie clínica: corea de Huntington. Evaluación Clínica (1994) Rev Chil Neuro-Psiquiat, 32, pp. 127-128
• Falush, D., Haplotype background, repeat length evolution, and Huntington's disease (2009) Am J Hum Genet, 85, pp. 939-942
• Warby, S.C., Visscher, H., Butland, S., Pearson, C.E., Hayden, M.R., Response to Falush: a role for cis-element polymorphisms in HD (2009) Am J Hum Genet, 85, pp. 942-945
• Quiroga Micheo, E., Vilaseca, A.B., Bonder, M.C., Quiroga Vergara, E.R., Frecuencia de los grupos sanguíneos y análisis de la progresiva disminución del factor Rh negativo en la población Argentina (1988) Revista Medicina, 48, pp. 355-360
• Tabrizi, S.J., Langbehn, D.R., Leavitt, B.R., Durr, A., Roos, R.A., Leavitt, B.R., Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data (2009) Lancet Neurol, 89, pp. 791-801
• Paulsen, J.S., Langbehn, D.R., Stout, J.C., Aylward, E., Ross, C.A., Nance, M., Predict-HD investigators and coordinators of the Huntington Study Group. Detection of Huntington's disease decades before diagnosis: the Predict-HD study (2008) JNeurol Neurosurg Psychiatry, 79, pp. 874-880
• Paulsen, J.S., Wang, C., Duff, K., Barker, R., Nance, M., Beglinger, L., PREDICT-HD investigators of the Huntington Study Group. Challenges assessing clinical endpoints in early Huntington disease (2010) Mov Disord, 25, pp. 2595-2603
• Stout, J.C., Paulsen, J.S., Queller, S., Solomon, A.C., Whitlock, K.B., Campbell, J.C., Neurocognitive signs in prodromal Huntington disease (2011) Neuropsychology, 25, pp. 1-14
• Gagnon, K.T., HD therapeutics - CHDI fifth annual conference (2010) Drugs, 13, pp. 219-223

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------